BofA cut target for Vertex Pharma stock from USD 672 to USD 667

Published on 10/14/2026 at 13:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 3.33 billion, up 12.00 percent year over year. Vertex Pharma stock was EUR 435.75 on October 14, 2026.

Target cut and upcoming results

BofA Securities lowered its Vertex target to USD 667 from USD 672 on October 12, 2026.
Second-quarter 2026 revenue reached USD 3.33 billion, up 12.00 percent year over year.
Vertex Pharma stock traded at EUR 435.75 at 1:03 p.m. CEST at Lang & Schwarz on October 14, 2026.
Third-quarter 2026 results are scheduled for November 2, 2026.

Aquarellbild der Boston-Skyline mit Segelbooten am Hafen im warmen Licht — Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten, Illustration mit AI erstellt.

Vertex Pharma (ISIN US92532F1003) was quoted at EUR 435.75 at Lang & Schwarz on October 14, 2026 at 1:03 p.m. CEST. BofA Securities had cut its price target for the company from USD 672 to USD 667 on October 12, 2026, while keeping a Buy rating, according to Investing.com.

Three dated developments

On August 3, 2026, Vertex reported second-quarter revenue of USD 3.33 billion, up 12.00 percent year over year, alongside GAAP net income of USD 1.10 billion and adjusted net income of USD 1.20 billion, according to Ticker Scout.

On October 9, 2026, Vertex presented interim ALYFTREK data from 48 children aged 2 to 5. Eighteen children, or 37.50 percent, successfully discontinued pancreatic enzyme replacement therapy, according to StockTitan.

On October 12, 2026, BofA Securities lowered its Vertex target from USD 672 to USD 667. The bank projected third-quarter Trikafta revenue of USD 2.42 billion against USD 2.54 billion consensus, a gap of 4.72 percent calculated from the consensus figure, as reported by Investing.com.

What does the target cut change?

The USD 5 reduction leaves the Buy rating intact, but it puts the cystic fibrosis franchise at the center of the near-term debate. BofA also forecast USD 688 million of third-quarter ALYFTREK revenue, above its USD 651 million consensus figure, and USD 83 million of CASGEVY revenue against USD 75 million consensus, according to Investing.com.

Results date is November 2

Vertex is scheduled to report third-quarter 2026 financial results on November 2, 2026, after the US market close, with a conference call at 4:30 p.m. ET, according to the company's release on Vertex Pharmaceuticals. The report will test whether newer products can offset pressure on Trikafta estimates.

Stock quote in euros

Vertex Pharma stock was at EUR 435.75 at Lang & Schwarz on October 14, 2026 at 1:03 p.m. CEST. The primary listing is Nasdaq in USD, while the euro quote gives German-market investors a separate intraday reference. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.